Josef T. Prchal,
MD
Languages Spoken: Czech, English
Josef Prchal, MD is a Professor in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the University of Utah. He is also named Huntsman Cancer Institute Investigator, and is a member of the Cell Response and Regulation Program and the Imaging, Diagnostics, and Therapeutics Program. In addition, he holds adjunct Professor appointments in Human Genetics and in Pathology. At his clinics at Huntsman Cancer Institute's Clinic 2B and at the George E. Wahlen Veteran's Medical Center, he sees benign red cell disorders and Philadelphia chromosome-negative myeloproliferative neoplasms.
For questions regarding Dr. Prchal's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at www.huntsmancancer.org or (801) 587-4630.
Clinical Locations
Hematology Clinic
801-585-2626
Fax: (801) 585-3854
Veterans Administration Medical Center
Myeloproliferative Disorders Clinic801-585-2626
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor Human Genetics - Adjunct Professor Pathology - Adjunct Professor |
| Academic Divisions | Hematology/BMT |
| Board Certification | American Board of Internal Medicine (Internal Medicine) Educational Commission for Foreign Medical Graduates Licentiate of the Medical Council of Canada Royal College of Physicians and Surgeons of Canada Royal College of Surgeons of Canada |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.9/ 5
Care provider's explanation of condition/problem
4.8/ 5
Care provider's effort to include me in decisions
4.8/ 5
Wait time at clinic
4.4/ 5
Care provider's concern for questions & worries
4.8/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
February 01, 2022
HUNTSMAN CANCER CENTER
This experience has been far-and-above better than any I've received at my previous provider in houston; I am very confident in the doctor's expertise and level of care
UofU Patient
January 27, 2022
HUNTSMAN CANCER CENTER
Dr Prchal is an amazing doctor. He answered all my questions and provided me with all the information I needed to decide about clinical trials for Myelofibrosis.
UofU Patient
January 19, 2022
HUNTSMAN CANCER CENTER
Issue has yet to be resolved.
UofU Patient
December 19, 2021
HUNTSMAN CANCER CENTER
He's a very knowledgeable, brilliant physician who has a difficult time relating his plan to the patient. I would still recommend him based on his knowledge and expertise.
UofU Patient
December 06, 2021
HUNTSMAN CANCER CENTER
Was declared cured of leukemia..great day
UofU Patient
November 15, 2021
HUNTSMAN CANCER CENTER
Prchal always makes sure you clearly understand his findings and diagnosis - including acknowledgment of the unknowns
UofU Patient
October 19, 2021
HUNTSMAN CANCER CENTER
Good experience
UofU Patient
October 06, 2021
HUNTSMAN CANCER CENTER
Noticed biopsy scab on shoulder. Mentioned that the type of skin cancer can be a side effect of medication and the possibility that may Indicate a change of drugs. My dermatology physician mentioned that he has had other patients of Dr.Prchal
UofU Patient
October 02, 2021
HUNTSMAN CANCER CENTER
Dr Prchal ia an outstanding physician.
UofU Patient
September 13, 2021
HUNTSMAN CANCER CENTER
We are waiting for test results.
UofU Patient
September 06, 2021
HUNTSMAN CANCER CENTER
I felt much better when I left.
UofU Patient
September 04, 2021
HUNTSMAN CANCER CENTER
Respected my decision not to take procrit shots when anemia is just below the concern.Immediately picked up on my observation that a skin cancer had been discovered on my shoulder and that I was going for treatment. Told me to watch this because skin cancers can be a side effect of my medication and to tell dermatologist of this.
UofU Patient
August 15, 2021
HUNTSMAN CANCER CENTER
Dr. Prchal is always professional, knowledgeable, and caring. Excellent.
UofU Patient
July 17, 2021
HUNTSMAN CANCER CENTER
Always look forward to seeing our dr. He is very highly recommended
UofU Patient
July 10, 2021
HUNTSMAN CANCER CENTER
Dr Prchal has always provided me with the very best of care.
UofU Patient
July 04, 2021
HUNTSMAN CANCER CENTER
Terrific
UofU Patient
May 16, 2021
HUNTSMAN CANCER CENTER
Very Good!
UofU Patient
April 17, 2021
HUNTSMAN CANCER CENTER
I have been seeing Dr Prchal for about 16 years. He has been an excellent doctor and given excellent care.
UofU Patient
April 11, 2021
HUNTSMAN CANCER CENTER
Love Dr Prchal
UofU Patient
April 10, 2021
HUNTSMAN CANCER CENTER
Dr. Prchal is amazing he helped save my life
UofU Patient
April 10, 2021
HUNTSMAN CANCER CENTER
All went well
UofU Patient
March 20, 2021
HUNTSMAN CANCER CENTER
Dr Prchal is the finest researcher/clinician I've ever experienced. I'm grateful for the 8 years of extended life I've received because of his knowledge and concern - and, after the many years of tests, procedures and various courses of chemotherapy, he has become a dear friend.
UofU Patient
March 06, 2021
HUNTSMAN CANCER CENTER
I have been a patient for almost ten years--Dr. Prychal has always done well on all of these.
UofU Patient
March 01, 2021
HUNTSMAN CANCER CENTER
very informitive
UofU Patient
February 01, 2021
HUNTSMAN CANCER CENTER
outstanding
UofU Patient
January 31, 2021
HUNTSMAN CANCER CENTER
Always a great experience with Dr. Prchal and his staff, including RNs!
UofU Patient
December 26, 2020
HUNTSMAN CANCER CENTER
Excellent discussion about COVID vaccine availability and my diagnosis. My husband is included in discussions as an active participant. On my own I did not have a procrit injection even though anemia numbers were down because I don't like the possible side effects and I did think I felt that much better. Dr. Prchal was supportive of my decisions I decided on my own to postpone procrit injenctions to 7 weeks--no change in my hemocrit numbers... and I don't like possible side effecrts.
UofU Patient
December 20, 2020
HUNTSMAN CANCER CENTER
The best way to communicate with your Doctor. it saved me 250 mile round trip to visit with the Doctor.
UofU Patient
November 28, 2020
HUNTSMAN CANCER CENTER
After I filled out the last Huntsman survey, I was contacted by Dr. Prchal on a Sunday afternoon to discuss a concern. I'm not accustomed to, not do I expect, that kind of concern.
UofU Patient
November 18, 2020
HUNTSMAN CANCER CENTER
Dr. Prachal is wonderful and we trust his judgment completely.
UofU Patient
November 14, 2020
HUNTSMAN CANCER CENTER
I have been a patient of Dr. Prchal's for almost 10 years..we have always had a good response from him.
UofU Patient
November 01, 2020
HUNTSMAN CANCER CENTER
great experience
UofU Patient
September 29, 2020
HUNTSMAN CANCER CENTER
Ongoing condition is being monitored and meds being adjusted as necessary.
UofU Patient
September 22, 2020
HUNTSMAN CANCER CENTER
awesome
UofU Patient
September 20, 2020
HUNTSMAN CANCER CENTER
Dr.Prchal is wonderful. would never go to any one else. Kind, empathetic, concerned, caring
UofU Patient
September 06, 2020
HUNTSMAN CANCER CENTER
I am always so impressed with every person I interact with at the hospital. I always receive amazing care.
UofU Patient
July 20, 2020
HUNTSMAN CANCER CENTER
VERY GOOD
UofU Patient
June 11, 2020
HUNTSMAN CANCER CENTER
very thorough
Josef Prchal, MD is a Professor in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the University of Utah. He is also named Huntsman Cancer Institute Investigator, and is a member of the Cell Response and Regulation Program and the Imaging, Diagnostics, and Therapeutics Program. In addition, he holds adjunct Professor appointments in Human Genetics and in Pathology. At his clinics at Huntsman Cancer Institute's Clinic 2B and at the George E. Wahlen Veteran's Medical Center, he sees benign red cell disorders and Philadelphia chromosome-negative myeloproliferative neoplasms.
For questions regarding Dr. Prchal's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at http://www.huntsmancancer.org or (801) 587-4630.
Academic Locations
Research Statement
Dr. Prchal’s career started when he was a medical student at Charles University (Universita Karlova-Karls-Universität) in Prague where he received a Purkynje' Medal for Medical Student Research for analysis of African students with G6PD deficiency. After emigrating to Canada in 1968 after the invasion of then Czechoslovakia, he did post-graduate training at the University Toronto and received a Research Award from the Royal College of Medicine for training with Ernest Beutler to learn biochemical genetics. He was recruited to the University of Alabama, then spent a year of sabbatical at Y.W. Kan’s lab (HHI, San Francisco) where he learned recombinant DNA technology. In 2000 he was recruited to Baylor College of Medicine in Houston and then in 2006 to the University of Utah. His major research focus has been the molecular defects of erythrocytes, with recent emphasis on genetic regulations of responses to hypoxia.
His honors include: Anniversary Medal of Universita Karlova (650 years) for Outstanding Research; Michael E. DeBakey Excellence in Research Award (2005); Honorary Doctor, Olomouc University (Alma Mater of Gregor Mendel) 2011; ASH Henry M. Stratton Medal Basic Science (2017) for Outstanding Contribution for the Fundamental Understanding of Red Cell Disorders; Inducted to Membership to Bolivian Academy of Sciences (2018).
He has published 374 peer-reviewed papers and 171 book chapters, editorials, and reviews. H-index 72; Citations 21251, i10 index 298.
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor Human Genetics - Adjunct Professor Pathology - Adjunct Professor |
| Academic Divisions | Hematology/BMT |
| Board Certification | American Board of Internal Medicine (Internal Medicine) Educational Commission for Foreign Medical Graduates Licentiate of the Medical Council of Canada Royal College of Physicians and Surgeons of Canada Royal College of Surgeons of Canada |
Research Interests
- Polycythemia
- Erythrocyte Disorders
- Hematopoiesis
Education History
| Fellowship | Toronto General Hospital Laboratory and Clinical Hematology Fellow, 1975 |
| Residency | University of Toronto, Department of Medicine Pathology Resident, 1975 |
| Fellowship | University of Toronto, Department of Medicine Hematology/Oncology Fellow, 1975 |
| Research Fellow | City of Hope National Medical Center Research Research Fellow, 1974 |
| Residency | University of Toronto, Dept of Medicine Internal Medicine Resident, 1972 |
| Internship | University of Toronto, Dept of Medicine Rotating Internship Intern, 1970 |
| Fellowship | Charles University School of Medicine Biochemistry Postdoctoral Research Associate, 1968 |
| Professional Medical | Charles University M.D., 1968 |
Selected Publications - Journal Articles
Journal Article
- Shrimali NM, Agarwal S, Kaur S, Bhattacharya S, Bhattacharyya S, Prchal JT, Guchhait P (2021). α-Ketoglutarate Inhibits Thrombosis and Inflammation by Prolyl Hydroxylase-2 Mediated Inactivation of Phospho-Akt. EBioMedicine, 73, 103672.
- Abou-Ismail MY, Prchal JT, Deininger MW, Parker CJ, Lim MY (2021). Anticoagulation management post-transjugular intrahepatic portosystemic shunt in portal hypertension associated with myeloproliferative neoplasms. Blood Coagul Fibrinolysis, 32, 578-583.
- Sirdah M, Reading NS, Vankayalapati H, Prchal JT (2021). A computational study of structural differences of binding of NADP+ and G6P substrates to G6PD Mediterraneanc.563T, G6PD A-c.202A/c.376G, G6PD Cairoc.404C and G6PD Gazac.536A mutations. Blood Cells Mol Dis, 89, 102572.
- Bhattacharya S, Shrimali NM, Mohammad G, Koul PA, Prchal JT, Guchhait P (2021). Gain-of-function Tibetan PHD2D4E;C127S variant suppresses monocyte function: A lesson in inflammatory response to inspired hypoxia. EBioMedicine, 68, 103418.
- Feusier JE, Arunachalam S, Tashi T, Baker MJ, VanSant-Webb C, Ferdig A, Welm BE, Rodriguez-Flores JL, Ours C, Jorde LB, Prchal JT, Mason CC (2021). Large-Scale Identification of Clonal Hematopoiesis and Mutations Recurrent in Blood Cancers. Blood Cancer Discov, 2(3), 226-237.
- Thiagarajan P, Parker CJ, Prchal JT (2021). How Do Red Blood Cells Die? Front Physiol, 12, 655393.
- Chan XY, Volkova E, Eoh J, Black R, Fang L, Gorashi R, Song J, Wang J, Elliott MB, Barreto-Ortiz SF, Chen J, Lin BL, Santhanam L, Cheng L, Lee FS, Prchal JT, Gerecht S (2021). HIF2A gain-of-function mutation modulates the stiffness of smooth muscle cells and compromises vascular mechanics. iScience, 24(4), 102246.
- Gordeuk VR, Shah BN, Zhang X, Thuma PE, Zulu S, Moono R, Reading NS, Song J, Zhang Y, Nouraie M, Campbell A, Minniti CP, Rana SR, Darbari DS, Kato GJ, Niu M, Castro OL, Machado R, Gladwin MT, Prchal JT (2020). The CYB5R3c .350C>G and G6PD A alleles modify severity of anemia in malaria and sickle cell disease. Am J Hematol, 95(11), 1269-1279.
- Xu G, van Bruggen R, Gualtieri CO, Moradin N, Fois A, Vallerand D, De Sa Tavares Russo M, Bassenden A, Lu W, Tam M, Lesage S, Girouard H, Avizonis DZ, Deblois G, Prchal JT, Stevenson M, Berghuis A, Muir T, Rabinowitz J, Vidal SM, Fodil N, Gros P (2019). Bisphosphoglycerate Mutase Deficiency Protects against Cerebral Malaria and Severe Malaria-Induced Anemia. Cell Rep, 32(12), 108170.
- Bahr TM, Henry E, Hulse W, Baer VL, Prchal JT, Bhutani VK, Christensen RD (2020). Early Hyperbilirubinemia in Neonates with Down Syndrome. J Pediatr, 219, 140-145.
- Gangaraju R, Song J, Kim SJ, Tashi T, Reeves BN, Sundar KM, Thiagarajan P, Prchal JT (2019). Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv, 4(6), 1115-1130.
- Swierczek S, Prchal JT (2020). Clonal hematopoiesis in hematological disorders: Three different scenarios. Exp Hematol, 83, 57-65.
- Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann JM, Agarwal AM, Clair P, Addada J, Lambert J, Salmon M, Gleich GJ, Cross NCP, Constantinescu SN, OHare T, Prchal JT, Deininger MW (2019). JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood, 134(26), 2388-2398.
- Babosova O, Kapralova K, Raskova Kafkova L, Korinek V, Divoky V, Prchal JT, Lanikova L (2019). Iron chelation and 2-oxoglutarate-dependent dioxygenase inhibition suppress mantle cell lymphoma's cyclin D1. J Cell Mol Med, 23(11), 7785-7795.
- Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Papaemmanuil E, Salama M, Singer-Weinberg R, Rampal R, Goldberg JD, Barbui T, Mesa R, Dueck AC, Hoffman R (2019). Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood, 134(18), 1498-1509.
- Lanikova L, Babosova O, Prchal JT (2019). Experimental Modeling of Myeloproliferative Neoplasms. Genes (Basel), 10(10).
- Christensen RD, Malleske DT, Lambert DK, Baer VL, Prchal JT, Denson LE, Gerday E, Weaver Lewis KA, Shepherd JG (2015). Measuring End-Tidal Carbon Monoxide of Jaundiced Neonates in the Birth Hospital to Identify Those with Hemolysis. Neonatology, 109(1), 1-5.
- Nussenzveig RH, Pham HT, Perkins SL, Prchal JT, Agarwal AM, Salama ME (2015). Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden. Leuk Lymphoma, 57(6), 1429-35.
- Ge RL, Simonson TS, Gordeuk V, Prchal JT, McClain DA (2015). Metabolic aspects of high-altitude adaptation in Tibetans. Exp Physiol, 100(11), 1247-55.
- Simonson TS, Huff CD, Witherspoon DJ, Prchal JT, Jorde LB (2015). Adaptive genetic changes related to haemoglobin concentration in native high-altitude Tibetans. Exp Physiol, 100(11), 1263-8.
- Prchal JT (2015). Genetic selection by high altitude: Beware of experiments at ambient conditions. Proc Natl Acad Sci U S A, 112(33), 10080-1.
- Song J, Yoon D, Christensen RD, Horvathova M, Thiagarajan P, Prchal JT (2015). HIF-mediated increased ROS from reduced mitophagy and decreased catalase causes neocytolysis. J Mol Med (Berl), 93(8), 857-66.
- Pomicter AD, Eiring AM, Senina AV, Zabriskie MS, Marvin JE, Prchal JT, OHare T, Deininger MW (2015). Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. Exp Hematol, 43(7), 537-45.e1-11.
- Christensen RD, Lambert DK, Henry E, Yaish HM, Prchal JT (2014). End-tidal carbon monoxide as an indicator of the hemolytic rate. Blood Cells Mol Dis, 54(3), 292-6.
- Sarangi S, Lanikova L, Kapralova K, Acharya S, Swierczek S, Lipton JM, Wolfe L, Prchal JT (2014). The homozygous VHL(D126N) missense mutation is associated with dramatically elevated erythropoietin levels, consequent polycythemia, and early onset severe pulmonary hypertension. Pediatr Blood Cancer, 61(11), 2104-6.
- Sangle N, Cook J, Perkins S, Teman CJ, Bahler D, Hickman K, Wilson A, Prchal J, Salama ME (2014). Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis. Appl Immunohistochem Mol Morphol, 22(9), 663-8.
- Lorenzo FR, Huff C, Myllymki M, Olenchock B, Swierczek S, Tashi T, Gordeuk V, Wuren T, Ri-Li G, McClain DA, Khan TM, Koul PA, Guchhait P, Salama ME, Xing J, Semenza GL, Liberzon E, Wilson A, Simonson TS, Jorde LB, Kaelin WG Jr, Koivunen P, Prchal JT (2014). A genetic mechanism for Tibetan high-altitude adaptation. Nat Genet, 46(9), 951-6.
- Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M, Bacigalupo A, Rambaldi A, Scarano M, Klisovic RB, Gupta V, Andreasson B, Mascarenhas J, Wetzler M, Vannucchi AM, Prchal JT, Najfeld V, Orazi A, Weinberg RS, Miller C, Barosi G, Silverman LR, Prosperini G, Marchioli R, Hoffman R (2014). MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood, 124(7), 1183-91.
- Tashi T, Feng T, Koul P, Amaru R, Hussey D, Lorenzo FR, RiLi G, Prchal JT (2014). High altitude genetic adaptation in Tibetans: no role of increased hemoglobin-oxygen affinity. Blood Cells Mol Dis, 53(1-2), 27-9.
- Zhang X, Zhang W, Ma SF, Desai AA, Saraf S, Miasniakova G, Sergueeva A, Ammosova T, Xu M, Nekhai S, Abbasi T, Casanova NG, Steinberg MH, Baldwin CT, Sebastiani P, Prchal JT, Kittles R, Garcia JG, Machado RF, Gordeuk VR (2014). Hypoxic response contributes to altered gene expression and precapillary pulmonary hypertension in patients with sickle cell disease. Circulation, 129(16), 1650-8.
- Dickinson RE, Milne P, Jardine L, Zandi S, Swierczek SI, McGovern N, Cookson S, Ferozepurwalla Z, Langridge A, Pagan S, Gennery A, Heiskanen-Kosma T, Hamalainen S, Seppanen M, Helbert M, Tholouli E, Gambineri E, Reykdal S, Gottfreethsson M, Thaventhiran JE, Morris E, Hirschfield G, Richter AG, Jolles S, Bacon CM, Hambleton S, Haniffa M, Bryceson Y, Allen C, Prchal JT, Dick JE, Bigley V, Collin M (2014). The evolution of cellular deficiency in GATA2 mutation. Blood, 123(6), 863-74.
- Kapralova K, Lanikova L, Lorenzo F, Song J, Horvathova M, Divoky V, Prchal JT (2014). RUNX1 and NF-E2 upregulation is not specific for MPNs, but is seen in polycythemic disorders with augmented HIF signaling. Blood, 123(3), 391-4.
- Christensen RD, Nussenzveig RH, Reading NS, Agarwal AM, Prchal JT, Yaish HM (2014). Variations in both alpha-spectrin (SPTA1) and beta-spectrin ( SPTB ) in a neonate with prolonged jaundice in a family where nine individuals had hereditary elliptocytosis. Neonatology, 105(1), 1-4.
- Reading NS, Sirdah MM, Tarazi IS, Prchal JT (2014). Detection of nine Mediterranean beta-thalassemia mutations in Palestinians using three restriction enzyme digest panels: a reliable method for developing countries. Hemoglobin, 38(1), 39-43.
- Ye Z, Liu CF, Lanikova L, Dowey SN, He C, Huang X, Brodsky RA, Spivak JL, Prchal JT, Cheng L (2014). Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells. Stem Cells, 32(1), 269-78.
- Zhang X, Zhang W, Ma SF, Miasniakova G, Sergueeva A, Ammosova T, Xu M, Nekhai S, Nourai M, Wade MS, Prchal JT, Garcia JGN, Machado RF, Gordeuk VR (2014). Iron deficiency modifies gene expression variation induced by augmented hypoxia sensing. Blood Cells Mol Dis, 52(1), 35-45.
- Nussenzveig RH, Christensen RD, Prchal JT, Yaish HM, Agarwal AM (2014). Novel alpha-spectrin mutation in trans with alpha-spectrin causing severe neonatal jaundice from hereditary spherocytosis. Neonatology, 106(4), 355-7.
Case Report
- Bahr TM, Lozano-Chinga M, Agarwal AM, Meznarich JA, Yost CC, Li P, Reading NS, Prchal JT, Christensen RD (2020). A Novel Variant in G6PD (c.1375C>G) Identified from a Hispanic Neonate with Extreme Hyperbilirubinemia and Low G6PD Enzymatic Activity. Neonatology, 117(4), 532-535.
- Christensen RD, Yaish HM, Wiedmeier SE, Reading NS, Pysher TJ, Palmer CA, Prchal JT (2013). Neonatal death suspected to be from sepsis was found to be kernicterus with G6PD deficiency. Pediatrics, 132(6), e1694-8.
- Boonyawat B, Dhanraj S, Al Abbas F, Zlateska B, Grunenbaum E, Roifman CM, Steele L, Meyn S, Blanchette V, Scherer SW, Swierczek S, Prchal J, Zhu Q, Torgerson TR, Ochs HD, Dror Y (2013). Combined de-novo mutation and non-random X-chromosome inactivation causing Wiskott-Aldrich syndrome in a female with thrombocytopenia. J Clin Immunol, 33(7), 1150-5.
Editorial
- Song J, Christensen RD, Thiagarajan P, Prchal JT (2021). Does neocytolysis exist after descent from high altitude? Acta Physiol (Oxf), 233(3), e13713.
- Prchal JT, Gordeuk VR (2021). HIF-2 inhibitor, erythrocytosis, and pulmonary hypertension. Blood, 137(18), 2424-2425.
- Song J, Tashi T, Prchal JT (2019). Editorial Comment on: Inhibition of Suicidal Erythrocyte Death by Chronic Hypoxia by Tang et al. (From: Tang F, Feng L, Li R, Wang W, Liu H, Yang Q, Ge R-L. High Alt Med Biol 2019;20:112-119; DOI: 10.1089/ham.2017.0159). High Alt Med Biol, 20(2), 120-121.
- Mascarenhas J, Mesa R, Prchal J, Hoffman R (2014). Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials. Haematologica, 99(6), 945-9.
Letter
- Reeves BN, Kim SJ, Song J, Wilson KJ, Henderson MW, Key NS, Pawlinski R, Prchal JT (2021). Tissue Factor Activity Is Increased in Neutrophils from JAK2 V617F-mutated Essential Thrombocythemia and Polycythemia Vera Patients. [Letter to the editor]. Am J Hematol.
- Meznarich JA, Rets A, Agarwal AM, Christensen RD, Reading NS, Kuypers FA, Prchal JT (2021). Novel, de novo, beta-globin variant with decreased oxygen affinity (HBB:c.317T>A, "Hemoglobin St. George") in a healthy child with low oxygen saturations and anemia. [Letter to the editor]. Am J Hematol, 96(12), E448-E450.
- Kim SJ, Song J, Reading NS, Lautersztain J, Kutlar A, Agarwal AM, Coetzer TL, Prchal JT (2021). Novel mechanism of hereditary pyropoikilocytosis phenotype due to co-inheritance of β globin and α spectrin mutations. [Letter to the editor]. Am J Hematol, 96(5), E150-E154.
- Zhang X, Song J, Shah BN, Nekhai S, Miasnikova G, Sergueeva A, Prchal JT, Gordeuk VR (2020). Peripheral blood mononuclear cells show prominent gene expression by erythroid progenitors in diseases characterized by heightened erythropoiesis. [Letter to the editor]. Br J Haematol, 190(1), e42-e45.
- Gordeuk VR, Miasnikova GY, Sergueeva AI, Lorenzo FR, Zhang X, Song J, Stockton DW, Prchal JT (2019). Thrombotic risk in congenital erythrocytosis due to up-regulated hypoxia sensing is not associated with elevated hematocrit. [Letter to the editor]. Haematologica, 105(3), e87-e90.
- Gangaraju R, Carroll AJ, Prchal JT (2019). Response to interferon treatment in essential thrombocythemia with inv(3)(q21q26). [Letter to the editor]. Ann Hematol.
- Swierczek S, Lima LT, Tashi T, Kim SJ, Gregg XT, Prchal JT (2015). Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms. [Letter to the editor]. Leukemia, 29(12), 2432-4.
- Sergueeva AI, Miasnikova GY, Polyakova LA, Nouraie M, Prchal JT, Gordeuk VR (2015). Complications in children and adolescents with Chuvash polycythemia. [Letter to the editor]. Blood, 125(2), 414-5.
- Salama ME, Swierczek SI, Tashi T, Warby CA, Reading NS, Prchal JT (2014). Calreticulin mutated prefibrotic-stage myelofibrosis and PMF represent an independent clone from coexisting CLL. [Letter to the editor]. Blood, 124(10), 1691-2.
- Wang L, Swierczek SI, Lanikova L, Kim SJ, Hickman K, Walker K, Wang K, Drummond J, Doddapaneni H, Reid JG, Muzny DM, Gibbs RA, Wheeler DA, Prchal JT (2014). The relationship of JAK2(V617F) and acquired UPD at chromosome 9p in polycythemia vera. [Letter to the editor]. Leukemia, 28(4), 938-41.
- Wang L, Swierczek SI, Drummond J, Hickman K, Kim SJ, Walker K, Doddapaneni H, Muzny DM, Gibbs RA, Wheeler DA, Prchal JT (2014). Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes. [Letter to the editor]. Leukemia, 28(4), 935-8.
Global Impact
Education History
| Fellowship | Toronto General Hospital Laboratory and Clinical Hematology Fellow |
| Residency | University of Toronto, Department of Medicine Pathology Resident |
| Fellowship | University of Toronto, Department of Medicine Hematology/Oncology Fellow |
| Residency | University of Toronto, Dept of Medicine Internal Medicine Resident |
| Internship | University of Toronto, Dept of Medicine Rotating Internship Intern |
| Fellowship | Charles University School of Medicine Biochemistry Postdoctoral Research Associate |
| Professional Medical | Charles University M.D. |
Service
| 01/01/2003 | Member | Co-chair, Ad Hoc Committee on International Outreach | Global |
| 01/01/2003 | Member | Subcommittee on Eastern Europe | Eastern Europe |